Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells by Combining Therapeutic Antibodies With CD20-Specific Immunoligands Engaging NKG2D or NKp30

Blood - United States
doi 10.1182/blood.v124.21.1779.1779